Artiva BiotherapeuticsARTV +8.95%12 FCF Yield % is -17.15 as of Jun. 28, 2026. GuruFocus rates ARTV with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 1,416 Biotechnology companies, Artiva Biotherapeutics ranks worse than 63.49% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Artiva Biotherapeutics FCF Yield % Related Terms
Artiva Biotherapeutics FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Artiva Biotherapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artiva Biotherapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artiva Biotherapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Artiva Biotherapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artiva Biotherapeutics (ARTV) has a FCF Yield % of -17.15 as of Jun. 28, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Artiva Biotherapeutics and its competitors. According to the industry distribution chart, Artiva Biotherapeutics ranks #899 out of 1416 companies in the Biotechnology industry, placing it in the top 63.5%.
Is Artiva Biotherapeutics' FCF Yield % too high?
Artiva Biotherapeutics' current FCF Yield % is -17.15. Based on the distribution chart, Artiva Biotherapeutics ranks #899 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Artiva Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Artiva Biotherapeutics' FCF Yield % compare to ENTA and VNDA?
According to the Biotechnology industry distribution chart, Artiva Biotherapeutics ranks #899 out of 1416 companies for FCF Yield %. This places Artiva Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Artiva Biotherapeutics and its competitors. Artiva Biotherapeutics's current FCF Yield % is -17.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artiva Biotherapeutics stock overvalued right now?
Artiva Biotherapeutics (ARTV) has a current FCF Yield % of -17.15. The current FCF Yield % is -17.15. Artiva Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Artiva Biotherapeutics (ARTV), the current FCF Yield % is -17.15 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
12GF Score
Get the complete analysis for ARTV
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARTV has been successfully added to your 
